Conclusion Report:

Phase I Conclusion:

Phase I of the study concluded with no harmful affects to any of the 4 control horses selected and no affects noted on the fifth control horse given 5 times the standard serving.

Phase II Conclusion:

From the information gathered in this phase of the study, the supplement Sefacon™ has the following effects:

1. 100 percent success with regards to stopping the progression of the disease, in so much as no horse’s condition continued to deteriorate after treatment began.
2. 100 percent success with regards to overall improvement of the horse’s condition as all 5 equine improved in all areas of deficit.

All but one of the test horses (EPM Horse 5) returned to pre-infection status.  Although, EPM Horse 5 has made substantial improvements, she still exhibits impaired motor control when trying to run or perform at an extended trot.  However, EPM Horse 5 can carry a rider at a walk and trot for an extended time without incident.  She is improving slowly and may still regain more motor control.  EPM Horse 5 was the last horse treated and more time is needed to determine the long-term prognosis.

Phase III Conclusion:

The group of 20 EPM equine was selected, and the Sefacon was administered.  All the test subjects responded to the Sefacon, no complications were noted and as of this report, no re-infection has been reported. 

Phase IV Conclusion:

Antibody levels varied indicating re-exposure to S. Neurona protozoa.  Although antibody levels elevated and decreased, no equine became symptomatic.